Context: Disturbed circadian rhythms and sleep quality during pregnancy have been related to gestational weight gain and gestational diabetes mellitus (GDM), which affect postpartum glucose metabolism and future risk of type 2 diabetes.
G estational diabetes mellitus (GDM), a state of impaired glucose tolerance during pregnancy, is one of the most frequent pregnancy complications associated with postpartum glucose metabolism and future risk of type 2 diabetes (1). Pregnancy may disturb circadian rhythms and therefore, affect sleep quality (2) . Emerging data have shown that sleep alterations during pregnancy were associated with greater weight gain (3, 4) and an increased risk for GDM (5, 6) .
Circadian rhythms and sleep quality are closely regulated by melatonin, a key hormone determining the sleep-wake cycle in humans (7) . Melatonin receptor 1B (MTNR1B) is one of the seven transmembrane G-protein-coupled melatonin receptors expressed in the central nervous system and in the peripheral tissues, including pancreatic b-cells (8) . The MTNR1B gene encodes one of the two high-affinity receptors of melatonin (9) , which has been implicated in regulation of circadian rhythms. A variant in the MTNR1B gene, rs10830963, was recently identified to be associated with altered melatonin rhythm and melatonin signaling (10, 11) . Of note, the MTNR1B genotype has also been associated with obesity, fasting glucose levels, type 2 diabetes, and GDM in genome-wide association studies (12, 13) . Thus, we hypothesized that the MTNR1B genotype may affect postpartum glycemic changes in women with GDM.
In this study of a large cohort of women with a history of GDM, we examined the associations of the circadian rhythm-related MTNR1B genotype with postpartum changes in measures of glycemic traits. In addition, we particularly assessed the interactions between the MTNR1B genotype and gestational weight gain on the glycemic changes.
Subjects and Methods

Study population
The current study was a retrospective analysis based on the baseline survey of the Tianjin Gestational Diabetes Mellitus Prevention Program, an ongoing, randomized clinical trial among Han Chinese women with a history of GDM. The study protocol was approved by the Human Subjects Committee of the Tianjin Women's and Children's Health Center, and written consent was obtained from all participants at the baseline survey. Details of methodological issues have been described previously (14) (15) (16) . In brief, all pregnant women in six main areas of Tianjin, China, who had a diagnosis of GDM at 26 to 30 gestational weeks between 2005 and 2009 were invited to participate in a postpartum survey from August 2009 to July 2011 (n = 4644). The World Health Organization criteria for GDM (17) were adopted in the current study. Of the 4644 women who participated in the postpartum survey at 1 to 5 years after delivery, women who could not be contacted, refused, or did not meet the eligibility criteria were excluded (n = 3381). Chronic diseases that could seriously reduce life expectancy were excluded in the baseline survey of the Tianjin GDM Prevention Program because these diseases might affect weight change, and the patients might take medicines that affected the metabolic outcomes of interest. Other criteria for exclusion were the following: age ,20 or $50 years, taking medicines known to alter 2-hour oral glucose tolerance test (OGTT), pregnant during the follow-up period, or unable to give informed consent. Thus, a total of 1263 women with a history of GDM completed the postpartum survey (participation rate 27%). There were no differences in 2-hour OGTT concentration, fasting glucose concentration, and the prevalence of impaired glucose tolerance and diabetes at 26 to 30 gestational weeks among women who participated in the postpartum survey and those who did not (15) . In addition, we further excluded 238 women without genotype information, and these women were not different in clinical characteristics and biochemical markers from those included in the final analysis. After these exclusions, a total of 1025 women were included in the current study.
Measurements of weight change and other variables
Data on medical eligibility and lifestyle measures were collected by self-administered questionnaires. The questionnaire inquired about socio-demographic information, history of GDM, medical history (pregnancy hypertension, diabetes, hypertension, and hypercholesterolemia), family history of diseases (diabetes, hypertension, stroke, and cancer), smoking, alcohol intake, physical activity, sleeping, stress, and use of supplements. Dietary intake data were collected by means of a 3-day, 24-hour food record. The questionnaires and the 3-day, 24-hour food record have been validated in the China National Nutrition and Health Survey (18, 19) . Body weight and height had been collected longitudinally based on medical records before the baseline survey of the Tianjin Gestational Diabetes Mellitus Prevention Program. Postpartum weight was measured on the day of delivery, and prepregnancy and current body mass index (BMI; in kilograms per square meter) were calculated (Supplemental Fig. 1 ). The 2009 Institute of Medicine guideline was used to classify gestational weight gain into inadequate, adequate, and excessive (20) . Adequate gestational weight gain was defined by prepregnancy BMI as follows: 12. 
Measurements of glycemic traits
Changes in glycemic traits were calculated as difference in glucose and hemoglobin A1c (HbA1c) levels between postpartum 1 to 5 years (at the postpartum survey) and pregnancy. The glycemic traits were measured in plasma both during the pregnancy (26 to 30 gestational weeks, the time point when the women were diagnosed with GDM) and at the postpartum survey (Supplemental Fig. 1 ). Blood samples were collected from all participants after an overnight fast of at least 12 hours. Fasting glucose and 2 hour OGTT were measured using an automatic analyzer (TBA-120FR; Toshiba, Tokyo, Japan). Glycated HbA1c was measured by using automatic glycohemoglobin analyzer (ADAMS A1c HA-8160; Arkray, Kyoto, Japan).
Genotyping
DNA was extracted from the buffy coat fraction of centrifuged blood using a QIAamp Blood Maxi Kit (Qiagen, Chatsworth, CA). The MTNR1B single nucleotide polymorphism rs10830963 was genotyped by a quantitative real-time TaqMan PCR (Applied Biosystems, Foster City, CA). The success rate of genotyping was .98%. Replicated quality control samples (10%) were conducted with .99% concordance.
Statistical analysis
The Hardy-Weinberg equilibrium of the genotype and comparison of categorical variables were assessed by a x 2 test. Differences in continuous variables by gestational weight gain were tested by using general linear models. Changes in glycemic traits associated with each additional copy of the MTNR1B rs10830963 G allele by gestational weight gain categories were estimated using general linear models. Statistical adjustments were made for age, follow-up time, prepregnancy BMI, dietary fat (percent energy), sitting time, postpartum weight change, the level of corresponding glucose trait (continuous variable), family history of diabetes (yes or no), current smoking (yes or no), current alcohol drinking (yes or no), leisure-time physical activity (0, ,30, or $30 minutes per day), and GDM therapy (yes or no). The interaction between MTNR1B rs10830963 genotype and gestational weight gain was tested by the introduction of a product term for these variables in the model. We also calculated the multivariable-adjusted mean values of changes in glycemic traits according to gestational weight gain and the MTNR1B rs10830963 genotype by use of general linear models. Two-sided P , 0.05 was considered as statistically significant. Statistical analyses were calculated using SAS version 9.4 (SAS Institute, Cary, NC).
Results
The frequency of the circadian rhythm-related MTNR1B rs10830963 G allele was 45%, and genotype distribution was in accordance with the Hardy-Weinberg equilibrium (P = 0.41). Table 1 shows the characteristics of women with a history of GDM, according to the MTNR1B rs10830963 genotype. The MTNR1B genotype was not associated with any glycemic traits (fasting glucose, 2-hour OGTT, and HbA1c) during pregnancy but had a positive association with postpartum fasting glucose levels (P , 0.03). The frequency of the three categories of gestational weight gain was not different by the MTNR1B genotype.
When all women were analyzed together, no association was found between the MTNR1B genotype and postpartum glycemic changes (all P $ 0.08). We then performed a stratified analysis to examine the associations of the MTNR1B genotype with 1 to 5 years of postpartum glycemic changes, according to gestational weight gain categories (Table 2 ). Gestational weight gain significantly modified the association of the MTNR1B genotype with postpartum changes in 2-hour OGTT. After multivariable adjustment, changes in 2-hour OGTT, associated with each additional copy of the risk G allele, were 0.36, 0.20, and 20.19 mM in women with inadequate, adequate, and excessive gestational weight gain, respectively (for interaction, P = 0.028).
Gestational weight gain had a marginally significant effect modification on the genetic associations of postpartum changes in fasting glucose levels after multivariable adjustment but had no significant effect modification on the genetic associations of postpartum changes in HbA1c. Each additional copy of the risk G allele was associated with changes in fasting glucose of 0.14, 0.13, and 0.01 mM across categories of inadequate, adequate, and excessive gestational weight gain, respectively (for interaction, P = 0.069), and the corresponding changes in HbA1c were 20.02%, 0.12%, and 20.05% (for interaction, P = 0.143). The mean value (standard deviation) of postpartum changes of 2-hour OGTT in all participants was 22.11 (2.44) mM. Figure 1 presents multivariable-adjusted postpartum changes of 2-hour OGTT stratified by gestational weight gain and the MTNR1B genotype. An increasing number of the G alleles were associated with a decrease in 2-hour OGTT levels in women with excessive gestational weight gain, whereas an opposite directional association was found among women with inadequate or adequate gestational weight gain.
We also analyzed the association between 2-hour OGTT and gestational weight gain, according to the MTNR1B genotype. Figure 2 shows the predicted changes in 2-hour OGTT with gestational weight gain (per 1 kg) by the MTNR1B genotype. Gestational weight gain was associated with a greater postpartum reduction of 2-hour OGTT in women carrying the MTNR1B rs10830963 GG genotype (b = 20.10 mM, P = 0.001) than that in women carrying the CC or CG genotype (b = 20.02 mM, 20.03 mM, respectively; P = 0.34, 0.11, respectively).
Discussion
In this study of Chinese women with a history of GDM, we found bidirectional interactions between the circadian rhythm-related MTNR1B genetic variant and gestational weight gain on 1-to 5-year postpartum changes in 2-hour OGTT. The MTNR1B genotype was related to distinct postpartum changes in 2-hour OGTT in women with inadequate, adequate, and excessive gestational weight gain. In addition, women carrying the MTNR1B GG genotype showed a more pronounced relationship between gestational weight gain and improvement in 2-hour OGTT than women carrying the other genotypes.
Numerous studies suggest that gestational weight gain plays an important role in women's long-term weight trajectory and affects postpartum hyperglycemia and type 2 diabetes in later life, especially among those with a history of GDM (21, 22) . This study assesses the effect of gestational weight gain on the association between the circadian rhythm-related MTNR1B genotype and postpartum glycemic changes among women with a history of GDM. A unique finding in the current study is that the relation between gestational weight gain and postpartum changes in 2-hour OGTT significantly differed by the MTNR1B rs10830963 genotype. Insulin plays a central role in regulation of glucose metabolism. Both in vivo and in vitro, insulin secretion by the pancreatic islets is in a circadian manner, as a result of the melatonin action on the melatonin receptors inducing a phase shift in the cells (23) . The genetic variant in the MTNR1B gene may directly affect the circadian manner of insulin secretion by the pancreatic islets and subsequently affect glucose metabolism (8, 24) . The modification of gestational weight gain on the association between the MTNR1B and the postpartum changes in 2-hour OGTT did not exclude the existence of the potential direct genetic effect; instead, our data suggest that the genetic effect might differ among women with distinct gestational weight gain. Our findings are biologically plausible, as gestational weight gain may also disturb the circadian manner of insulin secretion (3, 4) -the pathway where interaction between gestational weight gain and the genotype may occur. We found that the risk G allele of the MTNR1B variant was associated with increased 2-hour OGTT levels among women with inadequate or adequate gestational weight gain but was related to the decreased 2-hour OGTT levels among women with excessive gestational weight gain. Such an opposite genetic effect could be fairly explained by the differential-susceptibility hypothesis, a theory suggesting that genes may be conceptualized as plastic because genetic risk can be modified by environmental factors, such as change in body weight (25, 26) . Previous studies suggested that the risk G allele was associated with the outcome of an intervention that targeted weight loss (27) , whereas only those not carrying the risk G allele benefited from the lifestyle intervention among women at high risk of GDM (28) . We assume that the magnitude of gestational weight gain may differently affect expression or activity of the MTNR1B genetic variant and subsequently affect glucose metabolism during the postpartum period.
Intriguingly, we found that the relation between gestational weight gain and postpartum glycemic changes differed according to the MTNR1B genotype-women carrying the GG genotype showed a stronger association of reduction in 2-hour OGTT changes with gestational weight gain than women carrying other genotypes. In a recall by genotype of the MTNR1B study, Tuomi et al. (11) demonstrated that the effect of melatonin on insulin secretion was inhibitory and in a genotype-specific fashion. For example, measures of insulin secretion were lower in the GG carriers of the MTNR1B genotype after 3 months of melatonin treatment, whereas the metabolic consequences of melatonin treatment in CC carriers were modest and restricted to fasting plasma glucose levels (11) . On the other hand, Grotenfelt et al. (28) found that women carrying the CC genotype of the MTNR1B had a lower risk of GDM in response to a lifestyle intervention than women carrying other genotypes. Further studies are warranted to explore the potential mechanisms underlying the different effects of the MTNR1B genotypes on glucose metabolism.
A major strength of our study is the repeated measures of weight and glycemic traits during and after pregnancy. Other strengths include the large sample size of women with a prior GDM and longitudinal analysis. However, a number of limitations should be noted. First, the measurement of clock parameters was not done in this study. We used a genetic marker related to circadian rhythm that could be a better marker than biomarkers in causal inference, according to the Mendelian randomization theory (29) . Second, even though the current study focused on women with a history of GDM, we acknowledged that it was also of interest to assess the relation between the MTNR1B genotypes and glucose metabolism in women without GDM, which were unfortunately not available in our study samples, and future studies are warranted to verify our findings in women without GDM. Third, we did not collect sufficient reproductive data, such as postpartum depression, which may influence weight change and glucose metabolism. In addition, we acknowledged that exclusions might affect the presence of the association; however, there were no differences between the women with GDM at 26 to 30 gestational weeks who participated and those who did not, with regard to age, fasting glucose, 2-hour OGTT concentrations, and the prevalence of impaired glucose tolerance and diabetes. Although the results of our study might not be generalized to other populations, future studies in different populations are warranted.
In summary, the results of the current study showed that gestational weight gain might modify the effect of the circadian rhythm-related MTNR1B rs10830963 variant on postpartum changes in 2-hour OGTT, and vice versa, among Chinese women with a history of GDM. These findings suggest that women carrying the GG genotype might particularly benefit by controlling gestational weight gain to avoid postpartum hyperglycemia.
